Oral Cladribine for Relapsing Multiple Sclerosis – Info on a Placebo-Controlled Study

Background Cladribine provides immunomodulation through selective targeting of lymphocyte subtypes. We report the results of a 96-week phase 3 trial of a short-course oral tablet therapy in patients with relapsing–remitting multiple sclerosis.

Conclusions Treatment with cladribine tablets significantly reduced relapse rates, the risk of disability progression, and MRI measures of disease activity at 96 weeks. The benefits need to be weighed against the risks. (ClinicalTrials.gov number,NCT00213135 [ClinicalTrials.gov] .)

To See Study: Method & Results and Source information click here